CytomX Therapeutics (CTMX) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Join SI Premium – FREE
CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of $0.04, $0.23 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $26.38 million versus the consensus estimate of $13.34 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Investing.com’s stocks of the week
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
